Clinical research
Eli Lilly’s SURPASS-4 trial program shows tirzepatide, significantly reduced blood glucose levels and body weight better than insulin glargine in adult patients with type 2 diabetes.
“The virus will not be eradicated through vaccination alone. That means... we need our medicines. That was a failure of 2020 that doesn’t get enough emphasis,” Jake Glanville, chief executive officer of Bay Area-based Centivax, told BioSpace in an interview.
Companies have already begun their announcements of new clinical studies for various treatment settings in preparation for ASCO 2021.
Shares of Voyager Therapeutics fell in aftermarket trading after its CEO and CMO announced plans to depart the company following clinical setbacks with a Parkinson’s disease program.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Sarepta Therapeutics announced its gene therapy candidate, SRP-9001, shows “robust expression and consistent safety profile.”
Several biopharmaceutical companies have submitted NDAs to the U.S. FDA covering treatment indications ranging from an opioid overdose, bipolar disorder and rare disease.
Medicago and GSK announced their positive interim data from a mid-range study of a plant-based vaccine for COVID-19.
The U.S. FDA scolded CytoDyn for misrepresenting its clinical trial results for Leronlimab in COVID-19. Here’s what FDA has to say regarding CytoDyn Leronlimab.
Please check out the biopharma industry’s COVID-19 stories that are trending for May 18, 2021.
PRESS RELEASES